The largest database of trusted experimental protocols

5 protocols using mar1 5a3

1

Immunoblotting and Chromatin Immunoprecipitation Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary Abs used for immunoblotting were anti-β-actin (AC-74) and anti-Flag (M2) from Sigma, anti-IκBα (a gift from Prof. R. Hay, Dundee University, UK), anti-phospho-JNK (Thr183/Tyr185, 44-682G) from Biosource, anti-p38 (#9212), anti-phospho-p38 (Thr180/Tyr182, #9211), anti-JNK (#9252), anti-phospho-ERK1/2 (Thr202/Tyr204, #4377) and anti-phospho-STAT1 (Tyr701, #9171) from Cell Signaling Technology. The secondary Abs for immunoblotting were IRDye 680LT anti-mouse, IRDye 800CW anti-rabbit and IRDye 680LT anti-goat (LI-COR Biosciences). Primary Abs for confocal microscopy were anti-p65 (F-6, sc-8008) from Santa Cruz and anti-IRF3 (#51-3200) from Invitrogen, while secondary Abs were Alexa Fluor 647 anti-mouse or Alexa Fluor 488 anti-rabbit (Invitrogen). Abs used for ChIP were anti-Pol II (N-20, sc-899X), anti-p65 (C-20, sc-372X), anti-IRF1 (M-20, sc-640X) and anti-IRF8 (C-19, sc-6058X) from Santa Cruz, anti-IRF3 (#51-3200) from Invitrogen and isotype-control rabbit IgG (Sigma). The neutralizing IFNAR1 Ab (MAR1-5A3, #16-5945) was purchased from eBioscience.
+ Open protocol
+ Expand
2

Blocking IFNAR receptor in astrocytes and neurons

Check if the same lab product or an alternative is used in the 5 most similar protocols
Astrocytes and cortical neurons were treated with 5000 U/ml IFNαB/D [37 (link)] 16 h before infection, and virus titers were determined by focus-forming assays. The IFNAR receptor was blocked using monoclonal antibodies as previously described [4 (link)]. In brief, cells were incubated for 2 h with either 10 μg/mL MAR1-5A3 (eBioscience, 16-5945-85 [38 (link)]) or IgGI κ isotype control (eBioscience 14-4714-85). After 2 h of incubation, the medium was removed and cells were infected for 1 h. After the infection, the inoculum was replaced with medium containing 10 μg/mL antibody.
+ Open protocol
+ Expand
3

Interferon and NKG2D Blockade in Lupus

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female B6.MRL/lpr mice were treated with anti-IFNAR1 mAb (MAR1-5A3; eBioscience) or anti-NKG2D mAb (CX5; eBioscience) as previously described30 (link), 31 (link). Anti-IFNAR1 mAb or cIg injections were started at 15 wk of age, when the appearance of disease manifests, as suggested by detectable autoantibody titers and proteinuria (i.p., 500 μg for three consecutive days, followed by 250 μg three times per week until experiment termination). Similarly, injections of anti-NKG2D mAb or cIg were started at the same age (i.p. on days 1 and 5 with 8 μg/g of anti-NKG2D mAb (CX5) twice weekly).
+ Open protocol
+ Expand
4

Differentiation of TH1 and TH17 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the differentiation of TH1 cells35 (link), CD45.1+OT-II CD4+ T cells (2×105) were cultured with pDCs (2×104) in the presence or absence of IMQ (5 μg/ml) in combination with OVA323-339 peptide (1 μM), anti-IL-4 mAb (10 μg/ml; 11B11, BD Biosciences) and recombinant mouse IL-2 (0.2 ng/ml; Wako Pure Chemicals) for 3 days in 96-well flat-bottomed plates. For the differentiation of TH17 cells35 (link), CD45.1+OT-II CD4+ T cells (2×105) were cultured with pDCs (2×104) in the presence or absence of IMQ (5 μg/ml) in combination with OVA323–339 peptide (1 μM), anti-IFN-γ mAb (10 μg/ml; R4-6A2, BD Biosciences), anti-IL-4 mAb (10 μg/ml; 11B11), recombinant mouse IL-2 (0.2 ng/ml) and recombinant human transforming growth factor (TGF)-β1 (10 ng/ml; Wako Pure Chemicals) for 3 days in 96-well flat-bottomed plates. In some experiments, anti-IL-6 mAb (10 μg/ml; MP5-20F3, eBioscience), anti-IL-12 mAb (10 μg/ml; C17.8, eBioscience) or anti-IFNAR1 mAb (10 μg/ml; MAR1-5A3, eBioscience) was added to the culture. Analysis of the expression of IFN-γβ and/or IL-17 among gated CD4+ T cells was performed by flow cytometry as described above.
+ Open protocol
+ Expand
5

Knockdown Experiments and Cellular Stimulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
All knockdown experiments were performed using the Lipofectamine RNAiMAX transfection reagent (Invitrogen) with siRNA delivered at a concentration of either 20 or 50 nM in serum-depleted medium (OptiMEM; Invitrogen) as per the manufacturer’s instructions. Reverse transfections were employed with cells added to preformed siRNA:lipofectamine complexes pre-incubated for 20 minutes. Subsequent cell stimulations or viral infections were performed 48 hours after initial siRNA knockdown. Reporter constructs were transfected using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer’s instructions.
MEFs were stimulated by transfection of 2 µg/ml poly(I:C) into the cells using Lipofectamine 2000 transfection reagent (Invitrogen) following the manufacturer’s instructions. Alternatively, MEFs were stimulated with 500 U/ml recombinant IFN-β (R&D Systems) for the indicated times. To block IFN-β-induced signaling, MEFs were pre-incubated with 10 µg/ml IFNαR1 antibody (MAR1-5A3, eBioscience, catalogue number 16-5945).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!